Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | UTRN | P46939 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032232 | 0.80 | NOTUM (0.49) | MAPTRAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL913579 | 0.80 | MAPT (1.00) | MAPTRAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL10344443 | 0.78 | ELANE (0.66) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL7186075 | 0.76 | F7 (0.54) | MAPTRAB9ANPC1HTTKMT2A | |
| SCHEMBL912820 | 0.75 | PBRM1 (0.67) | NOTUMCASP3F7F3UTRN | |
| SCHEMBL10741223 | 0.75 | HPN (0.61) | MAPTRAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL5385451 | 0.75 | HPN (0.52) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL4260589 | 0.75 | MAPT (0.40) | MAPTRAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL914214 | 0.74 | MAPT (1.00) | MAPTRAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL14273715 | 0.74 | KDM4E (0.58) | MAPTSMN1; SMN2HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| EP-1631295-B1 | USE OF CONDENSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | AREXIS AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| WO-2000030646-A1 | HETEROCYCLIC COMPOUNDS REGULATING CLOTTING | NOVO NORDISK A/S (DK) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | MAPT 2054/4885RAB9A 3514/4885NPC1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.